Years ago Dr. Missling said something akin to "Later on people will see why we proceeded the way we did".
As I look at the way things stand currently I wonder if the plan is becoming clearer.
A small Alzheimer's trial to introduce the world to blarcamesine. Then a ph2 PDD trial(double blinded placebo controlled in case results were even better than expected) to provide guidance for an anticipated ph3 PD/PDD trial.
Simultaneously, as Bio recently put forth, a series of Rett trials logically arranged to build upon each other.
I wonder if at the beginning the powers that be at Anavex believed they were going to change medicine in a profound way and the intelligent path forward was to start with a whisper and build to a crescendo.
As an aside, I think I speak for many on this board that we're pleased you've made additional share purchases along the way since your steadfast conviction has helped make the wait more tolerable.
Falconer, I've always appreciated your thoughts. Is it possible that with the different indications that Anavex is pursuing, that Dr M may ask for FDA approval for GABA and glutamate normalization, rather than a specific indication. That way if a person has a CNS disease with this problem, a doctor could prescribe it. There could be a so called list of diseases, that even though it had not been involved in a trial for your indication, blarcamesine would be an approved drug. I know that this would be an entirely new approach, but the FDA needs to up it's game when it comes to Anavex. With the MOA that blarcamesine has, there has been nothing before that can compare. Your thoughts?
falconer, how large is the world wide community for Hereditary Spastic Paraplegia (HSP)? Since Missling is going for rare diseases and is on a rare disease consul, I'm hoping for you that a trial can be started sometimes in the near future. It is interesting that injections of GABA seems to solve the problem or at the very least make big improvements, which is what A-273 Blarcamesine does per the trials Anavex is conducting, and with Rett it was done with a 5mg low doseage. Maybe at some point you could contact Missling about starting a trial with murine rats to see just for himself how well A-273 Blarcamesine works with increasing the GABA, and a human trial from there. Good luck in making it happen.